Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

IMMU $2.20 0.3800 +20.88%
SCLN $8.76 0.6500 +8.01%
VBLT $3.39 0.2300 +7.28%
PVCT $0.52 0.0298 +6.11%
SNSS $0.79 0.0250 +3.29%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

KITE $41.47 -5.7200 -12.12%
OHRP $3.16 -0.3700 -10.48%
PBYI $39.72 -4.2600 -9.69%
CRIS $1.42 -0.1500 -9.55%
ATRA $17.16 -1.6800 -8.92%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | Next > | Last >>

Dialogue Between Patients and Physicians Critical to Making "Best Choice" Prostate Cancer Treatment Decisions

(ASTRO) Jan 21, 2016 - In light of a treatment guide for low-risk prostate cancer patients published today by the Institute for Clinical and Economic Research (ICER) and Families USA, the American Society for Radiation Oncology (ASTRO) emphasizes the importance of discussion between patients and their providers and seeks to provide context for some of the treatment recommendations in the guide.
read press release 



Leap Therapeutics Presents Positive Data from Phase 1 Study of DKN-01 in Combination with Paclitaxel in Relapsed or Refractory Cancer of the Esophagus or Gastro-esophageal Junction

(Leap Therapeutics) Jan 21, 2016 - Leap Therapeutics, a biotechnology company developing novel therapeutics at the leading edge of cancer research, reported its first results of a clinical trial of its lead candidate DKN-01, a monoclonal antibody against the Dickkopf-1 (DKK1) protein.
read corporate press release 



Glowing Tumors That Could Improve Cancer Surgery Are Getting Closer To Reality

(Forbes) Jan 22, 2016 - When a patient is diagnosed with a solid tumor cancer, one of the first options for treatment is often surgical removal of the tumor.
read article 



Adjuvant Chemo Boosts Survival in Bladder Cancer

(MedPage Today) Jan 21, 2016 - Adjuvant chemotherapy following cystectomy was associated with improved overall survival compared with cystectomy alone in patients with locally advanced bladder cancer, according to a large observational study of patients in the National Cancer Database (NCDB).
read article (free registration required) 



MACRA: Learn the Basics, Get Ready for a Post-SGR World in Encore Webinar Presentation

(ASCO in Action) Jan 21, 2016 - ASCO will offer an encore presentation of the free webinar, "MACRA: Learn the Basics, Get Ready for a Post-SGR World," featuring a high-level overview of the Medicare Access and Chip Reauthorization Act of 2015 (MACRA) on Tuesday, Feb. 2, 2016 from 4 - 5:30 p.m. EST.
read article 



CMS Releases Medicaid Covered Outpatient Drugs Final Rule

(ACCC) Jan 22, 2016 - The Centers for Medicare & Medicaid Services (CMS) released final rulemaking changes to how the government pays for outpatient prescription drugs in the Medicaid program.
read article 



Consumer And Research Groups Release Cancer Guides For Patients

(KHN) Jan 22, 2016 - For many patients, getting information on various treatment options for a medical condition isn’t hard. Finding out which ones are the best bets for the money can be more difficult.
read article 



Phila. Cancer Summit Examines Promise Of Precision Medicine

(Philadelphia Inquirer) Jan 22, 2016 - Nearly a week after Vice President Biden visited Philadelphia to announce a new federal "moon shot" to battle cancer, the heads of six leading Pennsylvania cancer centers and other experts gathered in Center City on Thursday to discuss treatment and prevention developments, and sort the promise from the hype.
read article 



European Commission Approves Label Variation for ADCETRIS (Brentuximab Vedotin) to Include Data on Retreatment of Adult Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma (sALCL)

(Takeda) Jan 22, 2016 -Takeda Pharmaceutical Company Limited today announced that the European Commission (EC) has approved a Type II variation for ADCETRIS® (brentuximab vedotin) to include data on the retreatment of adult patients with relapsed or refractory (R/R) Hodgkin lymphoma or R/R systemic anaplastic large cell lymphoma (sALCL) who previously responded to ADCETRIS and who later relapse.
read corporate press release 



OncoMed Presents Updated Phase 1b Data for Demcizumab in First-Line Pancreatic Cancer at the Gastrointestinal Cancers Symposium

(StreetInsider) Jan 22, 2016 - OncoMed Pharmaceuticals Inc., a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, announced updated survival data from the company’s Phase 1b clinical trial of demcizumab (anti-DLL4, OMP-21M18) at the Gastrointestinal Cancers Symposium.
read article 



NewLink Genetics Presents Phase 1b Data of Indoximod in Combination With Gemcitabine/Nab-Paclitaxel for Patients With Metastatic Pancreatic Cancer That Show Encouraging Durable Responses With Delayed Pattern

(Yahoo! Finance) Jan 22, 2016 - NewLink Genetics Corporation announce the presentation of data that describe a combination therapy of indoximod, an IDO pathway inhibitor, plus gemcitabine/nab-paclitaxel, for patients with metastatic pancreatic cancer.
read article 



Investigational Combinations Using An ABRAXANE And Gemcitabine Foundation Lead ASCO GI Pancreatic Cancer Research

(TheStreet) Jan 22, 2016 - Celgene Corporation today announced that 10 studies highlighting combinations that include a foundation of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension)(albumin-bound) and gemcitabine are being presented during the 2016 ASCO Gastrointestinal Cancers Symposium (ASCO GI), establishing the therapy as the foundation for research in first-line metastatic pancreatic cancer.
read article 



Some Older Patients Get Unnecessary Cancer Screenings

(Reuters) Jan 21, 2016 - Some older patients may receive screening for breast or prostate cancer even though the tests aren’t recommended because they aren’t expected to live long enough to benefit from treatment, a U.S. study suggests.
read article 



Patient Groups Funded By Drugmakers Are Largely Mum On High Drug Prices

(USA Today) Jan 21, 2016 - Drug companies provide so much of the funding for major patient groups that many critics say they've stifled a key voice in the policy debate over soaring drug prices, especially over those for cancer.
read article 



Bristol-Myers Wins U.K. Nod for Melanoma Drug Despite Cost

(Bloomberg) Jan 21, 2016 - Bristol-Myers Squibb Co. won the endorsement of the U.K.’s health-cost regulator for the use of its drug Opdivo in skin-cancer patients after failing to win its recommendation for treating lung tumors.
read article 



Kyprolis Combination Approved for Relapsed Multiple Myeloma

(CureToday.com) Jan 21, 2016 - The FDA has approved Kyprolis (carfilzomib) in combination with dexamethasone or with Revlimid (lenalidomide) plus dexamethasone for patients with relapsed/refractory multiple myeloma following prior treatment with one to three lines of therapy, based on findings from the phase 3 ENDEAVOR trial.
read article 



NICE Draft Guidance Recommends Nivolumab For Advanced Skin Cancer

(NICE) Jan 22, 2016 - The National Institute for Health and Care Excellence (NICE) has today (Friday 22 January) said yes to nivolumab as monotherapy for treating advanced skin cancer in final draft guidance.
read press release 



European Commission Approves Label Variation for ADCETRIS (Brentuximab Vedotin) to Include Data on Retreatment of Adult Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma (sALCL)

(Takeda) Jan 22, 2016 -Takeda Pharmaceutical Company Limited today announced that the European Commission (EC) has approved a Type II variation for ADCETRIS® (brentuximab vedotin) to include data on the retreatment of adult patients with relapsed or refractory (R/R) Hodgkin lymphoma or R/R systemic anaplastic large cell lymphoma (sALCL) who previously responded to ADCETRIS and who later relapse.
read corporate press release 



FDA Approves New Kyprolis® (Carfilzomib) Combination Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma

(CNNMoney) Jan 21, 2016 - Amgen today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) of Kyprolis® (carfilzomib) for Injection in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.
read article 



Alkermes Depression Drug Fails in Studies, Shares Plunge

(Reuters) Jan 21, 2016 - Alkermes Plc said its drug for major depressive disorder did not meet the main goal of improving depression symptoms in two late-stage studies, sending its shares down 32 percent in premarket trading.
read article 



A Blood Test May Soon Tell If You Really Need Antibiotics

(TIME) Jan 20, 2016 - For the flu or strep, will antibiotics make you feel better, or will the drugs cause side effects and be an expensive waste of time? There may soon be a simple test to know for sure.
read article 



Drug Industry to Fight Superbugs Together With Governments

(Washington Post/Associated Press) Jan 20, 2016 - Dozens of makers of medicines and diagnostic tests have joined together in an unprecedented effort to tackle "superbugs" — infections that increasingly don't respond to drugs and threaten millions of people in countries rich and poor.
read article (free registration required) 



5 Accused of Stealing Drug Secrets From GlaxoSmithKline

(New York Times) Jan 20, 2016 - Federal prosecutors in Philadelphia said on Wednesday that they had indicted five people, including two research scientists, on charges of stealing trade secrets about drugs to treat cancer and other diseases from GlaxoSmithKline, the British drug giant.
read article 



Read New JOP Editorial on ASCO’s Efforts to Support the Cancer Journey in the Digital Era

(ASCO in Action) Jan 19, 2016 - A new editorial in the Journal of Oncology Practice (JOP) outlines ASCO’s efforts and successes in supporting cancer care in the digital era with its Clinical Oncology Treatment Plan and Summary (COTPS), the Interoperability Demonstration project, and development of CancerLinQ™, a learning health system for cancer.
read article 



Vice President Highlights CancerLinQ™ at World Economic Forum

(ASCO in Action) Jan 20, 2016 - On January 19, Vice President Joe Biden discussed ASCO’s CancerLinQ™ initiative as one of the “major undertakings” designed to advance the pace of progress in the fight against cancer as part of his new “moonshot” initiative at the World Economic Forum in Davos-Klosters, Switzerland.
read article